NCIt definition : A human monoclonal antibody directed against human vascular endothelial growth factor
receptor 2 (VEGFR-2; VEGFR2), with potential anti-angiogenesis and antineoplastic
activities. Upon administration, pulocimab specifically binds to and inhibits VEGFR-2
on vascular endothelial cells, which may inhibit tumor angiogenesis and tumor cell
proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in
angiogenesis and the proliferation, survival, migration and differentiation of endothelial
cells, is overexpressed in certain tumor types.;